Probiotics: Their Tiny Worlds Are Under Scrutiny

Image: Courtesy of Mark Neysmith, © Gregor Reid GUT REACTION: Researchers have found that Lactobacillus GR-1 and RC-14 can penetrate Escherichia coli biofilms, multiply, and survive. The human body plays host to a complex and thriving microbial ecosystem of vast numbers of tiny creatures. Some of these species, already well studied, can cause disease. But a renewed appreciation is growing for many lesser-known species called probiotics that help maintain health and may have the pote

Written byBob Beale
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

The human body plays host to a complex and thriving microbial ecosystem of vast numbers of tiny creatures. Some of these species, already well studied, can cause disease. But a renewed appreciation is growing for many lesser-known species called probiotics that help maintain health and may have the potential to prevent disease. A steady stream of research papers on this topic is making its way into scientific and medical journals. The food industry is especially active in studying probiotics because the gastrointestinal tract is one of the richest zones of biodiversity within the body, with at least 400 known species of bacteria commonly found there.

Apart from their possible inclusion in foods or their development as food additives, many medical, dental, and veterinary researchers are looking at a wide range of therapeutic possibilities for probiotics. They include the treatment of ear, intestinal, and urinary tract infections; reduction of blood cholesterol ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies